Truist raised the firm’s price target on BridgeBio (BBIO) to $80 from $66 and keeps a Buy rating on the shares. The firm has updated its model to reflect Attruby performance in Q3, positive Phase 3 data in ribitol in LGMD2I/R9, and positive Phase 3 data in encaleret in ADH1, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO: